CHEBI:4708 - doxazosin

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name doxazosin
ChEBI ID CHEBI:4708
Definition A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C23H25N5O5
Net Charge 0
Average Mass 451.47510
Monoisotopic Mass 451.18557
InChI InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
InChIKey RUZYUOTYCVRMRZ-UHFFFAOYSA-N
SMILES COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)C1COc2ccccc2O1
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
Application(s): antihypertensive agent
Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
alpha-adrenergic antagonist
An agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
vasodilator agent
A drug used to cause dilation of the blood vessels.
antihyperplasia drug
A drug used for the treatment of hyperplasia (increaced cell production within an organ or tissue).
View more via ChEBI Ontology
ChEBI Ontology
Outgoing doxazosin (CHEBI:4708) has role α-adrenergic antagonist (CHEBI:37890)
doxazosin (CHEBI:4708) has role antihyperplasia drug (CHEBI:59844)
doxazosin (CHEBI:4708) has role antihypertensive agent (CHEBI:35674)
doxazosin (CHEBI:4708) has role antineoplastic agent (CHEBI:35610)
doxazosin (CHEBI:4708) has role vasodilator agent (CHEBI:35620)
doxazosin (CHEBI:4708) is a N-acylpiperazine (CHEBI:46844)
doxazosin (CHEBI:4708) is a N-arylpiperazine (CHEBI:46848)
doxazosin (CHEBI:4708) is a aromatic amine (CHEBI:33860)
doxazosin (CHEBI:4708) is a benzodioxine (CHEBI:64096)
doxazosin (CHEBI:4708) is a monocarboxylic acid amide (CHEBI:29347)
doxazosin (CHEBI:4708) is a quinazolines (CHEBI:38530)
Incoming doxazosin mesylate (CHEBI:4709) has part doxazosin (CHEBI:4708)
IUPAC Name
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
INNs Sources
doxazosin WHO MedNet
doxazosina WHO MedNet
doxazosine WHO MedNet
doxazosinum WHO MedNet
Synonyms Sources
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin ChemIDplus
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin ChemIDplus
Doxazosin KEGG COMPOUND
Manual Xrefs Databases
954 DrugCentral
C06970 KEGG COMPOUND
D07874 KEGG DRUG
DB00590 DrugBank
DE2847623 Patent
Doxazosin Wikipedia
HMDB0014728 HMDB
LSM-4335 LINCS
US4188390 Patent
View more database links
Registry Numbers Types Sources
731849 Beilstein Registry Number Beilstein
731849 Reaxys Registry Number Reaxys
74191-85-8 CAS Registry Number KEGG COMPOUND
74191-85-8 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
17171413 PubMed citation Europe PMC
18559700 PubMed citation Europe PMC
Last Modified
22 February 2017